Glycosylation in mammalian cells involves more than 200 different glycosyltransferase genes. These enzymes and accessory proteins form a huge network and are involved in the synthesis of glycoproteins, proteoglycans, and glycolipids. Mammalian mutant cell lines lacking glycosyltransferase genes are generated by targeted knockout, knock-in, or modulation of endogenous gene expression. They are critical to understanding important functional genes associated with disease. Precision genomic technologies can edit the endogenous genes of virtually any cell line to carry disease-causing mutations that have been identified in disorders of glycosylation.
Fig.1 Overview of glycoengineering strategy. (Narimatsu, et al., 2021)
Gene therapy is receiving increasing attention, allowing us to quickly edit the genomes of model organisms, with the potential to be used in the treatment of a variety of human diseases and defects. The key to gene therapy is how to edit the genome with high specificity and deliver it to the target safely and effectively. CD BioGlyco provides clients with Gene Editing System Delivery Services based on Viral Vectors, physical delivery, and non-viral vectors. Our scientists choose the delivery vehicle that works best for you based on your specific.
Electroporation is a commonly used membrane-disruptive cellular cargo molecule delivery technique. It produces high genome editing efficiencies in more difficult-to-transfect cell lines and even primary cells, with less cell dependence and good reproducibility. We use electroporation technology to deliver small interfering ribonucleic acid (siRNA) and microRNA (miRNA) that specifically knock out oncogenes or proto-oncogenes to the target for potential treatment of various tumors or targeted therapy-resistant cancer stem cells (CSC). Electroporation technology quickly and efficiently inserts deoxyribonucleic acid (DNA) sequences larger than 1 kbp into specific sites in the genome of primary human T cells while maintaining good cell viability and function.
Fig.2 Electroporation-based glycogene delivery service. (CD BioGlyco)
CD BioGlyco utilizes an advanced Glycogenomics Platform to edit glycosylation genes for the treatment of various diseases. We will select the best editing, delivery, and analysis strategies to achieve the best treatment options. Contact us today to learn how CD BioGlyco provides genome delivery services for you.